NVS - Novartis Outlines Pure-Play Strategy Progress After Generics Business Spin-Off | Benzinga
Novartis AG (NYSE: NVS) has outlined the progress made in delivering its pure-play strategy, focused on four core therapeutic areas (Cardiovascular-Renal-Metabolic, Immunology, Neuroscience, Oncology), two plus three technology platforms (Chemistry, Biotherapeutics, xRNA, Radioligand, Gene & Cell Therapy) in four priority geographies (US, China, Germany, Japan).
Also Read: Novartis' Rare Kidney Disease Candidate Aces Late-Stage Study.
Last month, Sandoz Group AG (OTC: SDZNY) (OTC: SDZXF), a spin-off of Novartis, entered a new era as a standalone player in generic and ...